Logo image of BLTE

BELITE BIO INC - ADR (BLTE) Stock Price, Quote, News and Overview

NASDAQ:BLTE - Nasdaq - US07782B1044 - ADR - Currency: USD

59.465  +2.66 (+4.67%)

BLTE Quote, Performance and Key Statistics

BELITE BIO INC - ADR

NASDAQ:BLTE (7/3/2025, 7:05:17 PM)

59.465

+2.66 (+4.67%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High86.53
52 Week Low43.7
Market Cap1.92B
Shares32.28M
Float14.87M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO04-29 2022-04-29


BLTE short term performance overview.The bars show the price performance of BLTE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 -6 -8

BLTE long term performance overview.The bars show the price performance of BLTE in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of BLTE is 59.465 USD. In the past month the price decreased by -8.91%. In the past year, price increased by 30.69%.

BELITE BIO INC - ADR / BLTE Daily stock chart

BLTE Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 56.73 739.87B
JNJ JOHNSON & JOHNSON 15.52 375.37B
NVO NOVO-NORDISK A/S-SPONS ADR 18.64 307.35B
NVS NOVARTIS AG-SPONSORED ADR 14.67 240.76B
AZN ASTRAZENECA PLC-SPONS ADR 15.78 215.32B
MRK MERCK & CO. INC. 10.39 203.22B
PFE PFIZER INC 7.91 144.29B
SNY SANOFI-ADR 10.52 117.55B
BMY BRISTOL-MYERS SQUIBB CO 6.39 95.49B
GSK GSK PLC-SPON ADR 8.5 77.37B
ZTS ZOETIS INC 26.44 70.87B
TAK TAKEDA PHARMACEUTIC-SP ADR 63.92 47.92B

About BLTE

Company Profile

BLTE logo image Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. The company is headquartered in San Diego, California and currently employs 25 full-time employees. The company went IPO on 2022-04-29. The firm is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Company Info

BELITE BIO INC - ADR

12750 High Bluff Drive Suite 475

San Diego CALIFORNIA US

Employees: 20

BLTE Company Website

BLTE Investor Relations

Phone: 18582466240

BELITE BIO INC - ADR / BLTE FAQ

What is the stock price of BELITE BIO INC - ADR today?

The current stock price of BLTE is 59.465 USD. The price increased by 4.67% in the last trading session.


What is the ticker symbol for BELITE BIO INC - ADR stock?

The exchange symbol of BELITE BIO INC - ADR is BLTE and it is listed on the Nasdaq exchange.


On which exchange is BLTE stock listed?

BLTE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BELITE BIO INC - ADR stock?

11 analysts have analysed BLTE and the average price target is 86.7 USD. This implies a price increase of 45.8% is expected in the next year compared to the current price of 59.465. Check the BELITE BIO INC - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BELITE BIO INC - ADR worth?

BELITE BIO INC - ADR (BLTE) has a market capitalization of 1.92B USD. This makes BLTE a Small Cap stock.


How many employees does BELITE BIO INC - ADR have?

BELITE BIO INC - ADR (BLTE) currently has 20 employees.


What are the support and resistance levels for BELITE BIO INC - ADR (BLTE) stock?

BELITE BIO INC - ADR (BLTE) has a support level at 57.26 and a resistance level at 59.2. Check the full technical report for a detailed analysis of BLTE support and resistance levels.


Should I buy BELITE BIO INC - ADR (BLTE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BELITE BIO INC - ADR (BLTE) stock pay dividends?

BLTE does not pay a dividend.


What is the Price/Earnings (PE) ratio of BELITE BIO INC - ADR (BLTE)?

BELITE BIO INC - ADR (BLTE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).


What is the Short Interest ratio of BELITE BIO INC - ADR (BLTE) stock?

The outstanding short interest for BELITE BIO INC - ADR (BLTE) is 1.06% of its float. Check the ownership tab for more information on the BLTE short interest.


BLTE Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to BLTE. When comparing the yearly performance of all stocks, BLTE turns out to be only a medium performer in the overall market: it outperformed 67.38% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

BLTE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BLTE. BLTE has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BLTE Financial Highlights

Over the last trailing twelve months BLTE reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -15.25% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -25.71%
ROE -26.69%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-66.67%
Sales Q2Q%N/A
EPS 1Y (TTM)-15.25%
Revenue 1Y (TTM)N/A

BLTE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to BLTE. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners0.74%
Ins Owners1.4%
Short Float %1.06%
Short Ratio4.89
Analysts
Analysts83.64
Price Target86.7 (45.8%)
EPS Next Y-44.64%
Revenue Next YearN/A